E-cigarette maker Juul to explore options including financing

Business
Jul.18.2022

(Reuters) -Juul Labs Inc said on Friday it is in the early stages of exploring several options including financing alternatives, as the company deals with lawsuits and a probable ban on sales of its e-cigarettes by U.S. health regulators.

 

E-cigarette maker Juul to explore options including financing

Bloomberg News earlier reported, citing sources, that Juul's bankers at Centerview Partners are sounding out investors for a possible $400 million first-lien term loan due August 2023. (https://bloom.bg/3O9qStl)

The proceeds would help refinance an existing term loan, which has around $394 million outstanding and matures on the same date, the report added.

A spokesperson for Juul told Reuters that the company is looking at options to protect its business and to address the "impact of the FDA's now stayed order so we can continue offering our products to adult consumers who have or are looking to transition away from traditional cigarettes."

 

Centerview Partners declined to comment when contacted by Reuters.

 

Bloomberg News in its report said Juul was also considering a new $150 million second-lien term loan, which may have an August 2024 maturity, to help pay down some of the first-lien term loan and to increase liquidity, the report said.

 

Financing proposals for either loan are due July 21, according to the report.

 

Last month, the Food and Drug Administration (FDA) blocked sales of Juul e-cigarettes and said the applications "lacked sufficient evidence" to show that sale of the products would be appropriate for public health.

 

However, Juul appealed the agency's order and earlier this month FDA put on hold its ban saying it would do an additional review of the company's marketing application.

 

(Reporting by Ananya Mariam Rajesh in Bengaluru; Editing by Shailesh Kuber)

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

COP11 Concludes with Major Decisions on Global Tobacco Control
COP11 Concludes with Major Decisions on Global Tobacco Control
The Eleventh Session of the Conference of the Parties (COP11) to the WHO Framework Convention on Tobacco Control (FCTC) concluded in Geneva on November 22, with 160 Parties adopting major decisions on tobacco and nicotine regulation, environmental protection, sustainable financing, and tobacco industry liability. A landmark decision mandates a complete ban on the use and sale of tobacco and all novel nicotine products across all UN premises worldwide.
Nov.24 by 2FIRSTS.ai
Irish Vape Group Urges Full Scrutiny of Single-Use Vape Bill
Irish Vape Group Urges Full Scrutiny of Single-Use Vape Bill
Responsible Vaping Ireland (RVI) has urged TDs to fully scrutinise the Public Health (Single-Use Vapes) Bill 2025 as it comes before the Dáil for debate. Representing more than 3,300 independent vape retailers, RVI stressed that meaningful consultation with retailers and enforcement authorities is essential to ensure the ban meets its public health and environmental goals without unintended consequences.
Dec.17 by 2FIRSTS.ai
Expert Warns in 2Firsts Op-ed: Proposed COP11 Ban on Nicotine Pouches Would Be a Global Public Health Mistake
Expert Warns in 2Firsts Op-ed: Proposed COP11 Ban on Nicotine Pouches Would Be a Global Public Health Mistake
As global delegates prepare for COP11, a leaked EU position paper has sparked fresh debate over the future of nicotine pouch regulation. In an exclusive op-ed submitted to 2Firsts, Dr. Nveed Chaudhary, Chair of GINN’s Scientific Committee, argues that banning nicotine pouches would be a profound public health mistake—one that ignores harm reduction science and risks reversing global progress in smoking cessation.
Nov.03
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.
Nov.24 by 2FIRSTS.ai
U.S. Company TPB Q3 Earnings: Nicotine Pouch Sales Surge 628% YoY, First U.S. Production Line Planned
U.S. Company TPB Q3 Earnings: Nicotine Pouch Sales Surge 628% YoY, First U.S. Production Line Planned
Turning Point Brands (NYSE: TPB) released its financial results for the third quarter of 2025, reporting strong revenue and profit growth driven by surging Modern Oral (nicotine pouch) sales. The company announced plans to establish its first U.S.-based white pouch production line in 2026, marking a key step toward manufacturing localization.
Nov.06 by 2FIRSTS.ai
Product | Up to 100,000 Puffs and Over 2,000 Puffs per ml: MASKKING, MR FOG, HYPERBAR Roll Out Ultra High-Puff New Devices
Product | Up to 100,000 Puffs and Over 2,000 Puffs per ml: MASKKING, MR FOG, HYPERBAR Roll Out Ultra High-Puff New Devices
In 2025, disposable vapes are shifting from a “puff count race” to a focus on user experience. While 30,000–50,000 puffs has become mainstream, brands like MASKKING, MR FOG, and HYPERBAR are still launching higher-capacity products in the 60,000–100,000 puff range. Models with disclosed tank sizes all exceed 2,000 puffs per mL and commonly feature adjustable wattage and enhanced interactive functions.
Nov.14 by 2FIRSTS.ai